ClinicalTrials.gg
RecruitingNCT07450599CHINANEOUpdated Nov 5, 2026

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

A Phase 2 interventional study of Darolutamide and ADT in High-risk Localized Prostate Cancer, sponsored by Bayer. Recruiting at 23 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 5, 2026Site recruiting status changedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Planned enrollment
11th of 59
250 · median 80
Started
2026
with 8 others
Phase 2
29 of 59
16 open now
Primary completion
2028-10
later than 28 of 39 live
Registered
55th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 11th largest by planned enrollment, is one of 9 that started in 2026, is one of 29 in phase 2, reaches primary completion later than 28 of the 39 other live ones, and was the 55th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat men who have high-risk localized prostate cancer, which refers to a type of prostate cancer that is still confined to the prostate gland but has certain characteristics that make it more likely to grow and spread.

The study treatment darolutamide plus androgen deprivation therapy (ADT) is under development as treatment before surgery for men who have high-risk localized prostate cancer. Darolutamide works by blocking the attachment of androgen hormones to androgen receptors in cancer cells, thereby blocking cancer progression and growth. ADT is an established treatment that is used to lower the amount of androgen hormones (e.g.,testosterone) in the body.

The main purpose of this study is to learn how the cancer responds to the two different treatment durations (12 weeks or 24 weeks) of darolutamide combined with ADT used before the men undergo surgery to remove the prostate. For this, the researchers will compare the percentage of participants who either achieve complete response to the treatment (where no cancer cells are found) or with condition of minimal residual disease after the treatment (where only a small amount of cancer cells remains).

The study participants will be randomly (by chance) assigned to one of two treatment groups. Depending on the group, they will receive darolutamide tablets by mouth plus ADT administered under the skin for either 12 weeks or 24 weeks. No more than 30 days after the end of the treatments, study participants will be performed with surgery to remove the prostate.

Each participant will be in the study for approximately 29 to 32 months, including a screening phase of up to 28 days, 12 weeks or 24 weeks of treatment depending on the treatment groups, followed by the surgery no more than 30 days after the treatment, and a follow up phase of up to 2years after the surgery.

2 visits to the study site are planned during the screening phase, followed by 3 to 6 visits (every 28 days) during treatment. The treatment period ends with a visit within 7 days after the last dose of treatment.

During the study, the doctors and their study team will:

  • take blood and urine samples
  • check the participants' health parameters
  • do physical examinations
  • check if the participants' cancer has grown and/or spread using CT (computed tomography) or MRI (magnetic resonance imaging) and, if needed, bone scan
  • take tumor samples
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

About 30 days after the last dose of treatment, 5 weeks after the surgery and every 12 weeks thereafter, the study doctors and their team will check the participants' health and any changes in cancer. This follow-up period ends 2 years after the surgery.

03

Conditions studied

  • High-risk Localized Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years or older at the time of signing the .
  • Darolutamide-naïve participants who are with localized prostate adenocarcinoma who plan to receive radical prostatectomy (RP) and defined as high risk with National Comprehensive Cancer Network (NCCN) criteria (version 1.2025).
  • No evidence of distant based on computed tomography (CT), magnetic resonance imaging (MRI), and whole body bone scan (WBBS) within 42 days prior to start of study treatment.
  • Candidate for RP with pelvic lymph node dissection (PLND) or extended PLND (ePLND) as per the investigator.
  • Participants must have at least one of the following features according to NCCN definition of high-risk:

    • Gleason score ≥8, and/or
    • Prostate-specific antigen (PSA) >20 ng/mL measured during Screening and prior to randomization, or
    • Clinical stage ≥ T3a.
  • Participants with pelvic lymph node involvement (N1) can be included.
  • (ECOG) performance status score of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prostate cancer with known neuroendocrine (NE) differentiation or small cell features.
  • Evidence of disease. Minimum imaging requirements to exclude metastatic disease are diagnostic quality imaging of the chest, pelvis, and the abdomen (CT or MRI with intravenous [IV] contrast), and WBBS. Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion.
  • Intolerant to darolutamide or androgen deprivation therapy (ADT) treatment.
  • History of

    • Loss of consciousness or or stroke within 6 months prior to randomization, or
    • Significant cardiovascular disease within 6 months prior to randomization.
    • Any for RP.
  • Uncontrolled or treatment-resistant hypertension.
  • History of another within 5 years prior to randomization.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Darolutamide + ADT (12 weeks)

    Participants will receive darolutamide and androgen deprivation therapy (ADT) as neoadjuvant treatment for 12 weeks, followed by radical prostatectomy (RP).

    Drug: Darolutamide · Drug: ADT

  • Experimental
    Darolutamide + ADT (24 weeks)

    Participants will receive darolutamide and androgen deprivation therapy (ADT) as neoadjuvant treatment for 24 weeks, followed by radical prostatectomy (RP).

    Drug: Darolutamide · Drug: ADT

Interventions

  • Oral tablets of 600 mg twice daily (BID).

  • DrugADT

    Goserelin acetate implant (ZOLADEX), at a dose of 10.8 mg, will be administered subcutaneously every 12 weeks into the anterior abdominal wall below the navel line.

06

What researchers measure

Primary outcomes

  1. The proportion of participants achieving pathologic response rate (pRR: pathologic complete response [pCR] or minimal residual disease [MRD])

    pRR is defined as the proportion of participants with either condition of pCR or MRD at week 12 or 24 in corresponding arm. Proportion of participants with pCR is defined as the proportion of participants with no residual tumor detected in radical prostatectomy (RP) specimens following 12 or 24 weeks of neoadjuvant treatment of darolutamide and ADT per randomization. Proportion of participants with MRD is defined as the proportion of participants that have residual cancer burden (RCB) ≤0.25 cm\^3 in the RP specimens.

    Time frame: Completion of Follow-up 1, 30 days after last dose of study drug

Secondary outcomes

  1. Proportion of participants with pathologic complete response (pCR)

    Proportion of participants with pCR is defined as the proportion of participants with no residual tumor detected in radical prostatectomy (RP) specimens following 12 or 24 weeks of neoadjuvant treatment of darolutamide and ADT per randomization.

    Time frame: Completion of Follow-up 1, 30 days after last dose of study drug

  2. Percentage of participants with tumor downstaging (e.g. clinical T3 to pathologic T2)

    The pathology review will compare the T stage of tumor tissue at baseline (Screening) with the T stage of radical prostatectomy (RP) specimen at RP and calculate the proportion of participants whose tumor stage has decreased from the baseline T stage.

    Time frame: At baseline and immediately after radical prostatectomy

  3. Percentage of participants with positive surgical margin (PSM)

    PSM is defined as the presence of cancer cells at the edge of the tissue removed during surgery.

    Time frame: Immediately after radical prostatectomy

  4. Biochemical complete response (CR) rate prior to radical prostatectomy (RP) and at landmark timepoints post-RP

    Biochemical CR rate is defined as participants who attain serum prostate-specific antigen (PSA) level below 0.1 ng/mL (PSA \<0.1 ng/mL).

    Time frame: At pre-RP, at 5 weeks, 12 weeks post-RP, and every 3 months after that until Year 2 after RP or end of follow up

  5. Biochemical recurrent free survival since radical prostatectomy (RP) among participants with prostate-specific antigen (PSA) <0.1 ng/mL after RP

    Biochemical recurrent free survival is defined as time from RP to biochemical recurrence or death, whichever occurs first. The endpoint will be assessed only among participants with PSA \<0.1 ng/mL after RP. Biochemical recurrence is defined as PSA ≥0.1 ng/mL in 2 consecutive measurements after RP. The date of the first measurement defines the date of biochemical recurrence.

    Time frame: From RP to biochemical recurrence or death whichever occurs first, up to 2.5 years

  6. Incidence and severity of treatment-emergent adverse events (TEAEs) (including treatment-emergent serious adverse events [TESAEs])

    TEAEs are defined as AEs with an onset date on or after the first dose of study drug and up to the end-of-study drug plus 30 days or with an onset date prior to the first dose of study drug but worsening in intensity after the study drug. Events with missing onset dates will be included as treatment-emergent.

    Time frame: From first dose of study drug up to 30 days after the end of study drug administration

07

Study locations

17 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 29 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 29 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Mar 4, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Oct 15, 2028
CompletionEst.
Oct 15, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • The First Affiliated Hospital of Fujian Medical University · Fuzhou, ChinaNot yet recruiting→Recruiting
  • The Second Hospital & Clinical Medical School, Lanzhou University · Lanzhou, ChinaNot yet recruiting→Recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, ChinaNot yet recruiting→Recruiting
  • Renmin Hospital of Wuhan University · Wuhan, ChinaNot yet recruiting→Recruiting
  • Qilu Hospital of Shandong University · Jinan, ChinaNot yet recruiting→Recruiting
  • Shanghai General Hospital · Shanghai, ChinaNot yet recruiting→Recruiting
  • Dongyang People's Hospital · Dongyang, ChinaNot yet recruiting→Recruiting
  • Jinhua Municipal Central Hospital (Affiliated Jinhua Hospital, Zhejiang University School of Medicine) · Jinhua, ChinaNot yet recruiting→Recruiting
  • The first Affiliated Hospital of Guangzhou Medical University · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Nanfang Hospital · Guangzhou, ChinaNot yet recruiting→Recruiting
  • The Second Affiliated Hospital of Kunming Medical University · Kunming, ChinaNot yet recruiting→Recruiting
Show 4 added (4 China)
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
  • The first Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
  • The 2nd Hospital of Hebei Medical University · Shijiazhuang, China
  • Xinhua Hospital affiliated to shanghai jiao tong university school of medicine · Shanghai, China
Show 4 removed
  • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
  • The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
  • The Second Hospital of Hebei Medical University · Shijiazhuang, China
  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, China
across 2 updates, Oct 13, 2026 – Nov 5, 2026
Contact
Study contact's phone or email changed: •••2937→•••2937. See the current contact
Oct 13, 2026
Show all 2 updates
  1. Nov 5, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • The first Affiliated Hospital of Guangzhou Medical University · Guangzhou, ChinaNot yet recruiting→Recruiting
    • Nanfang Hospital · Guangzhou, ChinaNot yet recruiting→Recruiting
    • The Second Affiliated Hospital of Kunming Medical University · Kunming, ChinaNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites added, 4 sites removed. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, ChinaNot yet recruiting→Recruiting
    • The Second Hospital & Clinical Medical School, Lanzhou University · Lanzhou, ChinaNot yet recruiting→Recruiting
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, ChinaNot yet recruiting→Recruiting
    • Renmin Hospital of Wuhan University · Wuhan, ChinaNot yet recruiting→Recruiting
    • Qilu Hospital of Shandong University · Jinan, ChinaNot yet recruiting→Recruiting
    • Shanghai General Hospital · Shanghai, ChinaNot yet recruiting→Recruiting
    • Dongyang People's Hospital · Dongyang, ChinaNot yet recruiting→Recruiting
    • Jinhua Municipal Central Hospital (Affiliated Jinhua Hospital, Zhejiang University School of Medicine) · Jinhua, ChinaNot yet recruiting→Recruiting
    Show 4 added (4 China)
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
    • The first Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
    • The 2nd Hospital of Hebei Medical University · Shijiazhuang, China
    • Xinhua Hospital affiliated to shanghai jiao tong university school of medicine · Shanghai, China
    Show 4 removed
    • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
    • The First Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
    • The Second Hospital of Hebei Medical University · Shijiazhuang, China
    • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, China
    Contact Study contact's phone or email changed: •••2937→•••2937. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07450599
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Apr 27, 2026
Primary completion
Oct 15, 2028 (estimated)
Completion
Oct 15, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
0018888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Antiandrogens

Start the discussion